The INVOKE clinical trial

OKN4395 asset in clinical development, leading our precision oncology pipeline

OKN4395

The INVOKE study

The INVOKE study (OKN-4395-121) is a global, multicenter, Phase 1a/1b, first-in-human, open-label trial evaluating OKN4395 in patients with advanced solid tumors.

OKN4395 is Owkin’s first program to leverage our AI-powered Operating System, throughout the entire development process - from asset selection to clinical optimization⁠.

To learn more visit epkin.ai

The INVOKE study (OKN-4395-121; NCT06789172) is sponsored by Epkin (an affiliate of Owkin France).